Loading…
Reported covered position: Health Policy Advisor, Rep. Bilirakis; Health Policy Coordinator, House Energy and Commerce Committee
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mikaela Naylon Give Kids a Chance Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 1509/S. 752 - Accelerating Kids Access to Care Act of 2025, all provisions. H.R. 1262/S. 932 - Give Kids a Chance Act of 2025, all provisions.
Accelerating Kids’ Access to Care Act of 2025
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 1509/S. 752 - Accelerating Kids Access to Care Act of 2025, all provisions. H.R. 1262/S. 932 - Give Kids a Chance Act of 2025, all provisions.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2025 · first_quarter · Q1
H.R. 2666/S. 4204 - MVP Act, all provisions. H.R. 1968 - Full-Year Continuing Appropriations and Extensions Act, 2025, provisions related to health.
H.R. 1509/S. 752 - Accelerating Kids Access to Care Act of 2025, all provisions. H.R. 1262/S. 932 - Give Kids a Chance Act of 2025, all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Full-Year Continuing Appropriations and Extensions Act, 2025
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 2666/S. 4204 - MVP Act, all provisions. H.R. 1968 - Full-Year Continuing Appropriations and Extensions Act, 2025, provisions related to health.
CBO Scoring Accountability Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 2666/S. 4204 - MVP Act, all provisions. H.R. 1968 - Full-Year Continuing Appropriations and Extensions Act, 2025, provisions related to health.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 1509/S. 752 - Accelerating Kids Access to Care Act of 2025, all provisions. H.R. 1262/S. 932 - Give Kids a Chance Act of 2025, all provisions.
Give Kids a Chance Act of 2025
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 1509/S. 752 - Accelerating Kids Access to Care Act of 2025, all provisions. H.R. 1262/S. 932 - Give Kids a Chance Act of 2025, all provisions.
H.R. 2666/S. 4204 - MVP Act, all provisions. H.R. 1968 - Full-Year Continuing Appropriations and Extensions Act, 2025, provisions related to health.
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 2666/S. 4204 - MVP Act, all provisions. H.R. 10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025, issues related to PRV and the Accelerating Kids Access to Care Act. Issues related to the CMMI demonstration on Gene and Cell Therapy.
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 2666/S. 4204 - MVP Act, all provisions. H.R. 10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025, issues related to PRV and the Accelerating Kids Access to Care Act. Issues related to the CMMI demonstration on Gene and Cell Therapy.
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 2666 - MVP Act, all provisions. Issues related to the implementation of the CMMI demonstration on Gene Therapy.
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 2666/S. 4204 - MVP Act, all provisions. Issues related to the CMMI demonstration on Gene and Cell Therapy.
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 2666/S. 4204 - MVP Act, all provisions. Issues related to the CMMI demonstration on Gene and Cell Therapy.
Give Kids a Chance Act of 2024
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
Issues related to gene therapy and rare diseases. H.R. 4758 - Accelerating Kids Access to Care Act, all provisions. H.R. 3433 - Give Kids a Chance Act of 2024, all provisions.
Give Kids a Chance Act of 2024
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
Issues related to gene therapy and rare diseases. H.R. 4758 - Accelerating Kids Access to Care Act, all provisions. H.R. 3433 - Give Kids a Chance Act of 2024, all provisions.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
Issues related to gene therapy and rare diseases. H.R. 4758 - Accelerating Kids Access to Care Act, all provisions. H.R. 3433 - Give Kids a Chance Act of 2024, all provisions.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
Issues related to gene therapy and rare diseases. H.R. 4758 - Accelerating Kids Access to Care Act, all provisions. H.R. 3433 - Give Kids a Chance Act of 2024, all provisions.
H.R. 2666/S. 4204 - MVP Act, all provisions. Issues related to the CMMI demonstration on Gene and Cell Therapy.
H.R. 2666/S. 4204 - MVP Act, all provisions. H.R. 10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025, issues related to PRV and the Accelerating Kids Access to Care Act. Issues related to the CMMI demonstration on Gene and Cell Therapy.
H.R. 2666/S. 4204 - MVP Act, all provisions. Issues related to the CMMI demonstration on Gene and Cell Therapy.
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 2666 - MVP Act, all provisions. Issues related to the Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program Notice for Proposed Rulemaking (CMS-2434-P).
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
Issues related to the adoption of value-based payment arrangements. H.R. 2666 - MVP Act, all provisions.
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
Issues related to the adoption of value-based payment arrangements. H.R. 2666 - MVP Act, all provisions.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Inflation Reduction Act of 2022
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Inflation Reduction Act of 2022
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Inflation Reduction Act of 2022
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Inflation Reduction Act of 2022
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Elijah E. Cummings Lower Drug Costs Now Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Elijah E. Cummings Lower Drug Costs Now Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act: Issues regarding international reference drug pricing. Issues related to the adoption of value-based payment arrangements.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Inflation Reduction Act of 2022
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Accelerating Kids’ Access to Care Act
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Prescription Drug Pricing Reduction Act of 2019
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
S. 2543 - Prescription Drug Pricing Reduction Act (PDPRA): Section 208. Issues relating to the need for value-based payment arrangements.
Prescription Drug Pricing Reduction Act of 2019
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
S. 2543 - Prescription Drug Pricing Reduction Act (PDPRA): Section 208.
Prescription Drug Pricing Reduction Act of 2019
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
S. 2543 - Prescription Drug Pricing Reduction Act (PDPRA): Section 208.
Prescription Drug Pricing Reduction Act of 2019
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
Issues relating to gene therapy; Issues relating to the need for value-based payment arrangements; S. 2543 - Prescription Drug Pricing Reduction Act (PDPRA): Section 208.
Prescription Drug Pricing Reduction Act of 2019
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
S. 2543 - Prescription Drug Pricing Reduction Act (PDPRA): Provisions related to section 208, Risk-Sharing Value-Based Payment Agreements for covered outpatient drugs under Medicaid.
FDA Reauthorization Act of 2017
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
HR 2430/S 934, FDA Reauthorization Act of 2017
FDA Reauthorization Act of 2017
Client: SPARK THERAPEUTICS, INC. · Firm: SPARK THERAPEUTICS, INC.
HR 2430/S 934, FDA Reauthorization Act of 2017
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2024 · fourth_quarter · Q4
H.R. 2666/S. 4204 - MVP Act, all provisions. H.R. 10445 - Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025, issues related to PRV and the Accelerating Kids Access to Care Act. Issues related to the CMMI demonstration on Gene and Cell Therapy.
Issues related to gene therapy and rare diseases. H.R. 4758 - Accelerating Kids Access to Care Act, all provisions. H.R. 3433 - Give Kids a Chance Act of 2024, all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2024 · third_quarter · Q3
Issues related to gene therapy and rare diseases. H.R. 4758 - Accelerating Kids Access to Care Act, all provisions. H.R. 3433 - Give Kids a Chance Act of 2024, all provisions.
H.R. 2666/S. 4204 - MVP Act, all provisions. Issues related to the CMMI demonstration on Gene and Cell Therapy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2024 · second_quarter · Q2
Issues related to gene therapy and rare diseases.
H.R. 2666/S. 4204 - MVP Act, all provisions. Issues related to the CMMI demonstration on Gene and Cell Therapy.
88 FR 85593 Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights, all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2024 · first_quarter · Q1
H.R. 2666 - MVP Act, all provisions. Issues related to the implementation of the CMMI demonstration on Gene Therapy.
Issues related to gene therapy and rare diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2023 · fourth_quarter · Q4
H.R. 2666 - MVP Act, all provisions. Issues related to the Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program Notice for Proposed Rulemaking (CMS-2434-P).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2023 · third_quarter · Q3
Issues related to the adoption of value-based payment arrangements. H.R. 2666 - MVP Act, all provisions.
Issues related to gene therapies and rare diseases and conditions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2023 · second_quarter · Q2
Issues related to the adoption of value-based payment arrangements. H.R. 2666 - MVP Act, all provisions.
Issues related to gene therapies and rare diseases and conditions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2023 · first_quarter · Q1
Issues related to gene therapies and rare diseases and conditions.
Issues related to the adoption of value-based payment arrangements. MVP Act reintroduction, all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2022 · fourth_quarter · Q4
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Issues related to gene therapies and rare diseases and conditions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2022 · third_quarter · Q3
Issues related to gene therapies and rare diseases and conditions.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2022 · second_quarter · Q2
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements. H.R. 7389 - MVP Act, all provisions.
Issues related to gene therapies and rare diseases and conditions. Issues related to the Orphan Drug Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2022 · first_quarter · Q1
Issues related to gene therapies and rare diseases and conditions. Issues related to the Orphan Drug Tax Credit.
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2021 · fourth_quarter · Q4
H.R. 5376 - Build Back Better Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Issues related to gene therapies and one-time treatments. Issues related to policies and regulations impacting drugs for rare diseases and conditions and the Orphan Drug Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2021 · third_quarter · Q3
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act: Issues regarding international reference drug pricing. S. 1544, H.R. 3089 - Accelerating Kids Access to Care Act: Issues related to streamlined enrollment process for out-of-state Medicaid providers. Issues related to the adoption of value-based payment arrangements.
Issues related to gene therapies and one-time treatments. Issues related to policies and regulations impacting drugs for rare diseases and conditions and the Orphan Drug Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2021 · second_quarter · Q2
Issues related to gene therapies and one-time treatments. Issues related to policies and regulations impacting drugs for rare diseases and conditions.
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act: Issues regarding international reference drug pricing. Issues related to the adoption of value-based payment arrangements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2021 · first_quarter · Q1
Issues related to gene therapies and one-time treatments. Issues related to policies and regulations impacting drugs for rare diseases and conditions.
Issues related to the adoption of value-based payment arrangements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2020 · fourth_quarter · Q4
Issues relating to the adoption of value-based payment arrangements.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2020 · third_quarter · Q3
Issues relating to the adoption of value-based payment arrangements.
S. 2543 - Prescription Drug Pricing Reduction Act (PDPRA): Section 208.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2020 · second_quarter · Q2
S. 2543 - Prescription Drug Pricing Reduction Act (PDPRA): Section 208.
Issues relating to the adoption of value-based payment arrangements.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2020 · first_quarter · Q1
S. 2543 - Prescription Drug Pricing Reduction Act (PDPRA): Section 208. Issues relating to the need for value-based payment arrangements.
Filing targets: Centers For Medicare and Medicaid Services (CMS)
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2019 · fourth_quarter · Q4
Issues relating to gene therapy; Issues relating to the need for value-based payment arrangements; S. 2543 - Prescription Drug Pricing Reduction Act (PDPRA): Section 208.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2019 · third_quarter · Q3
Issues relating to gene therapy; Issues relating to the need for value-based payment arrangements.
S. 2543 - Prescription Drug Pricing Reduction Act (PDPRA): Provisions related to section 208, Risk-Sharing Value-Based Payment Agreements for covered outpatient drugs under Medicaid.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2019 · second_quarter · Q2
Issues relating to gene therapy; Issues relating to the need for value-based payment arrangements.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2019 · first_quarter · Q1
Issues relating to gene therapy; Issues relating to the need for value-based payment arrangements.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2018 · fourth_quarter · Q4
Issues relating to gene therapy; Issues relating to the need for value-based payment arrangements.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2018 · third_quarter · Q3
Issues relating to gene therapy; Issues relating to the need for value-based payment arrangements.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of the Vice President of the United States, SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2018 · second_quarter · Q2
gene therapy; the need for value-based payment arrangements
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2018 · first_quarter · 1A
gene therapy; the need for value-based payment arrangements
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2018 · first_quarter · Q1
gene therapy; the need for value-based payment arrangements
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2017 · fourth_quarter · Q4
gene therapy; the need for value-based payment arrangements
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2017 · third_quarter · Q3
HR 2430/S 934, FDA Reauthorization Act of 2017
SPARK THERAPEUTICS, INC. via SPARK THERAPEUTICS, INC.
2017 · third_quarter · RR
issues related to healthcare, FDA and Medicare/Medicaid, specifically those related to drug pricing and access